Teleflex Incorporated (TFX)
Teleflex Incorporated (TFX) is a global provider of medical technologies focused on solutions for healthcare providers and patients. Founded in 1943, the company specializes in products used in minimally invasive surgeries, anesthesiology, respiratory care, and vascular access, offering a broad portfolio aimed at improving clinical outcomes and healthcare efficiency. Its innovations support hospitals, clinics, and other medical facilities worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 15, 2025 | $0.34 | 2025-08-15 | 2025-08-15 |
| June 16, 2025 | $0.34 | 2025-05-20 | 2025-05-20 |
| March 17, 2025 | $0.34 | 2025-03-07 | 2025-03-07 |
| December 16, 2024 | $0.34 | 2024-11-15 | 2024-11-15 |
| September 16, 2024 | $0.34 | 2024-08-15 | 2024-08-15 |
Dividends Summary
- Teleflex Incorporated has issued 88 dividend payments over the past 22 years
- The most recent dividend was paid 37 days ago, on September 15, 2025
- The highest dividend payed out to investors during this period was $0.34 per share
- The average dividend paid during this period was $0.32 per share.
Company News
The global intravenous catheters market is projected to grow from USD 9.06 billion in 2024 to USD 16.47 billion by 2032, driven by rising chronic disease prevalence and increasing demand for outpatient and home-based IV therapies.
Teleflex has completed its acquisition of BIOTRONIK's Vascular Intervention business for €760 million, expanding its global presence in the cath lab and peripheral intervention market with a comprehensive portfolio of medical technologies.
Several S&P 500 stocks posted sharp declines in 2024, despite a generally bullish year for the index. These battered stocks could be ripe for a turnaround in 2025, as investors look for undervalued gems in the market.
Phibro Animal Health Corporation's robust sales of vaccines and medicated feed additives (MFAs) are driving growth in its Animal Health business. The company's focus on advancing nutritional specialties and vaccine technologies, along with a new vaccine production unit, instills optimism. However, adverse macroeconomic impacts and growing competi...